Clinical Trial Update: BAY 77-1931 Long-term Extension From Phase II Study [Phase 2]

View source ↗

Summary

Update on the long-term extension of BAY 77-1931 from a Phase II trial in hyperphosphatemia, including interim safety/tolerability observations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphosphatemia

Drugs mentioned

• BAY 77-1931

Snippet

Sponsor: Bayer | Conditions: Hyperphosphatemia | Phase 2 | Status: COMPLETED